Last reviewed · How we verify
WCK 5222
At a glance
| Generic name | WCK 5222 |
|---|---|
| Also known as | Cefepime and zidebactam combination |
| Sponsor | Wockhardt |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PHASE3)
- A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination. (PHASE1)
- Plasma and Intrapulmonary Concentrations Study of WCK 5222 (PHASE1)
- To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment (PHASE1)
- Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers (PHASE1)
- MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WCK 5222 CI brief — competitive landscape report
- WCK 5222 updates RSS · CI watch RSS
- Wockhardt portfolio CI